Glenmark Pharmaceuticals Limited (Glenmark) has launched the novel fixed-dose combination (FDC) drug – Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India. The company has launched this FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively.
Asthma is a major non-communicable disease that affects more than 34 million people in India, causing thousands of deaths every year. Glenmark became the first company in India to market the innovative FDC of Indacaterol, a long-acting beta-agonist and Mometasone Furoate, an inhaled corticosteroid which is approved by the DCGI.
While speaking on the development, Alok Malik, Group Vice President & Head, India Formulations – Glenmark Pharmaceuticals Ltd. said, “We are proud to introduce this novel fixed-dose combination Indamet®, which is the first of its kind in India; offering a world-class and affordable treatment option to both adults and adolescents 12 years of age and older suffering from uncontrolled asthma.”
